Silence Therapeutics Plc - ADR
SLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$495.48M
Close$
$0.11
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $495.48 Million |
|---|---|
| Enterprise Value | $489.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.89 |
| Beta | 1.38 |
| Outstanding Shares | 47,234,192 |
Return
| Return on Equity | 109.47% |
|---|---|
| Return on Assets | -46.98% |
| Return on Invested Capital | -66.05% |
Valuation & Multiples
| P/E Ratio | -2.43 |
|---|---|
| PEG | 5.1 |
| Price to Sales | - |
| Price to Book Ratio | 3.72 |
| Enterprise Value to Revenue | 583.66 |
| Enterprise Value to EBIT | -5.9 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$1.17 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6667▲ 166.67% |
|---|---|
| Total Calls | 18,900▲ Infinity% |
| Total Puts | 31,500▼ 20.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.15%▲ 3.85% |
|---|---|
| Total Invested | $102.08M▼ 3.77% |
| Investors Holding | 58▼ 1.00% |
ESG Score
No data
About Silence Therapeutics Plc
74 employees
CEO: David Solomon